Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders
Carregando...
Citações na Scopus
72
Tipo de produção
article
Data de publicação
2013
Editora
DOVE MEDICAL PRESS LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
NEUROPSYCHIATRIC DISEASE AND TREATMENT, v.9, p.493-500, 2013
Resumo
In the last two decades, a growing body of evidence has shown that lithium has several neuroprotective effects. Several neurobiological mechanisms have been proposed to underlie these clinical effects. Evidence from preclinical studies suggests that neuroprotection induced by lithium is mainly related to its potent inhibition of the enzyme glycogen synthase kinase-3 beta (GSK-3 beta) and its downstream effects, ie, reduction of both tau protein phosphorylation and amyloid-beta(42) production. Additional neuroprotective effects include increased neurotrophic support, reduced proinflammatory status, and decreased oxidative stress. More recently, neuroimaging studies in humans have demonstrated that chronic use is associated with cortical thickening, higher volume of the hippocampus and amygdala, and neuronal viability in bipolar patients on lithium treatment. In line with this evidence, observational and case registry studies have shown that chronic lithium intake is associated with a reduced risk of Alzheimer's disease in subjects with bipolar disorder. Evidence from recent clinical trials in patients with mild cognitive impairment suggests that chronic lithium treatment at subtherapeutic doses can reduce cerebral spinal fluid phosphorylated tau protein. Overall, convergent lines of evidence point to the potential of lithium as an agent with disease modifying properties in Alzheimer's disease. However, additional long-term studies are necessary to confirm its efficacy and safety for these patients, particularly as chronic intake is necessary to achieve the best therapeutic results.
Palavras-chave
lithium, Alzheimer's disease, prevention, GSK-3 beta, neuroprotection
Referências
- Aliyazicioglu R, 2007, TOHOKU J EXPT MED, V273, P79
- Alvarez G, 2002, BIPOLAR DISORD, V4, P153, DOI 10.1034/j.1399-5618.2002.01150.x
- Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7
- Amari L, 1999, ANAL BIOCHEM, V272, P1, DOI 10.1006/abio.1999.4169
- Aprahamian I, 2013, BR J PSYCHI IN PRESS
- Basselin M, 2007, J NEUROCHEM, V102, P761, DOI 10.1111/j.1471-4159.2007.04593.x
- BIRCH NJ, 1974, LANCET, V2, P965
- Burger S, 2009, INT J DEV NEUROSCI, V27, P517, DOI 10.1016/j.ijdevneu.2009.06.011
- CADE JFJ, 1949, MED J AUSTRALIA, V2, P349
- Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745
- Chen CL, 2006, MOL PHARMACOL, V70, P510, DOI 10.1124/mol.106.024059
- Cheung ZH, 2011, J NEUROCHEM, V118, P317, DOI 10.1111/j.1471-4159.2011.07314.x
- Contestabile A, 2013, J CLIN INVEST, V123, P348, DOI 10.1172/JCI64650
- de Sousa RT, 2011, NEUROSCI LETT, V494, P54, DOI 10.1016/j.neulet.2011.02.054
- Diniz BS, 2011, NEUROMOL MED, V13, P217, DOI 10.1007/s12017-011-8154-x
- Engel T, 2006, J NEUROCHEM, V99, P1445, DOI 10.1111/j.1471-4159.2006.04139.x
- Esselmann H, 2004, NEURODEGENER DIS, V1, P236, DOI 10.1159/000080992
- Fiorentini A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014382
- Foland LC, 2008, NEUROREPORT, V19, P221, DOI 10.1097/WNR.0b013e3282f48108
- Forester BP, 2008, BIPOLAR DISORD, V10, P691, DOI 10.1111/j.1399-5618.2008.00627.x
- Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044
- Forlenza OV, 2012, DRUG AGING, V29, P335, DOI 10.2165/11599180-000000000-00000
- Forlenza OV, 2011, J PSYCHIATR RES, V45, P220, DOI 10.1016/j.jpsychires.2010.06.002
- Fu ZQ, 2010, J ALZHEIMERS DIS, V21, P1107, DOI 10.3233/JAD-2010-100687
- Germana C, 2010, ACTA PSYCHIAT SCAND, V122, P481, DOI 10.1111/j.1600-0447.2010.01582.x
- Ghribi O, 2002, J NEUROCHEM, V82, P137, DOI 10.1046/j.1471-4159.2002.00957.x
- Guloksuz S, 2012, J AFFECT DISORDERS, V143, P148, DOI 10.1016/j.jad.2012.04.044
- Hampel H, 2009, J CLIN PSYCHIAT, V70, P922
- Hashimoto R, 2003, NEUROSCIENCE, V117, P55, DOI 10.1016/S0306-4522(02)00577-8
- Hooper C, 2007, EUR J NEUROSCI, V25, P81, DOI 10.1111/j.1460-9568.2006.05245.x
- Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x
- Kessing LV, 2008, ARCH GEN PSYCHIAT, V65, P1331, DOI 10.1001/archpsyc.65.11.1331
- Kessing LV, 2010, BIPOLAR DISORD, V12, P87, DOI 10.1111/j.1399-5618.2009.00788.x
- Khairova R, 2012, MOL MED REP, V5, P680, DOI 10.3892/mmr.2011.732
- Kim JS, 2004, J NEUROCHEM, V89, P324, DOI 10.1046/j.1471-4159.2004.02329.x
- Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
- Knijff EM, 2007, BIPOLAR DISORD, V9, P743, DOI 10.1111/j.1399-5618.2007.00444.x
- Leroy K, 2010, J ALZHEIMERS DIS, V19, P705, DOI [10.3233/JAD-2010-1276, 10.3233/JAD-2009-1276]
- Leyhe T, 2009, J ALZHEIMERS DIS, V16, P649, DOI 10.3233/JAD-2009-1004
- Li HF, 2011, J CEREBR BLOOD F MET, V31, P2106, DOI 10.1038/jcbfm.2011.75
- Li Q, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.33
- Li XH, 2007, BIOL PSYCHIAT, V61, P216, DOI 10.1016/j.biopsych.2006.02.027
- Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8
- Macdonald A, 2008, INT J GERIATR PSYCH, V23, P704, DOI 10.1002/gps.1964
- Machado-Vieira R, 2007, NEUROSCI LETT, V421, P33, DOI 10.1016/j.neulet.2007.05.016
- Machado-Vieira R, 2009, BIPOLAR DISORD, V11, P92, DOI 10.1111/j.1399-5618.2009.00714.x
- Mendes CT, 2009, EUR ARCH PSY CLIN N, V259, P16, DOI 10.1007/s00406-008-0828-5
- Moore GJ, 2009, J CLIN PSYCHIAT, V70, P699, DOI 10.4088/JCP.07m03745
- Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912
- Nahman S, 2012, INNATE IMMUN-LONDON, V18, P447, DOI 10.1177/1753425911421512
- Nitrini R, 2004, ALZ DIS ASSOC DIS, V18, P241
- Nivoli AMA, 2011, J AFFECT DISORDERS, V129, P14, DOI 10.1016/j.jad.2010.05.018
- Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102
- Nocjar C, 2007, NEUROSCIENCE, V150, P774, DOI 10.1016/j.neuroscience.2007.09.063
- Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104
- Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868
- O'Brien WT, 2011, J CLIN INVEST, V121, P3756, DOI 10.1172/JCI45194
- Pan JQ, 2011, NEUROPSYCHOPHARMACOL, V36, P1397, DOI 10.1038/npp.2011.24
- Pasquali L, 2010, BEHAV PHARMACOL, V21, P473, DOI 10.1097/FBP.0b013e32833da5da
- Patel NS, 2010, J NEUROCHEM, V112, P66, DOI 10.1111/j.1471-4159.2009.06426.x
- Patel S, 2002, J MOL BIOL, V315, P677, DOI 10.1006/jmbi.2001.5271
- Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640
- Polter A, 2010, NEUROPSYCHOPHARMACOL, V35, P1761, DOI 10.1038/npp.2010.43
- Rametti A, 2008, NEUROSCI LETT, V434, P93, DOI 10.1016/j.neulet.2008.01.034
- Ravikumar B, 2004, NEUROREPORT, V15, P2443, DOI 10.1097/00001756-200411150-00001
- Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007
- Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
- Rybakowski JK, 2010, INT J NEUROPSYCHOPH, V13, P617, DOI 10.1017/S1461145710000404
- Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169
- Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
- Shim SS, 2007, PROG NEURO-PSYCHOPH, V31, P343, DOI 10.1016/j.pnpbp.2006.09.008
- Shimada K, 2012, NEUROBIOL DIS, V46, P101, DOI 10.1016/j.nbd.2011.12.050
- Silverstone PH, 2003, INT CLIN PSYCHOPHARM, V18, P73, DOI 10.1097/01.yic.0000056178.28244.f5
- Straten G, 2011, CURR ALZHEIMER RES, V8, P853
- Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j
- Sugawara H, 2010, J NEURAL TRANSM, V117, P155, DOI 10.1007/s00702-009-0340-8
- Suwalska A, 2010, NEUROPSYCHOBIOLOGY, V62, P229, DOI 10.1159/000319949
- Sy M, 2011, AM J PATHOL, V178, P2811, DOI 10.1016/j.ajpath.2011.02.012
- Takahashi M, 1999, J NEUROCHEM, V73, P2073
- Terao T, 2006, PROG NEURO-PSYCHOPH, V30, P1125, DOI 10.1016/j.pnpbp.2006.04.020
- Tong LQ, 2004, J NEUROSCI, V24, P6799, DOI 10.1523/JNEUROSCI.5463-03.2004
- Voytovych H, 2012, NEUROPHARMACOLOGY, V63, P274, DOI 10.1016/j.neuropharm.2012.03.023
- Yasuda S, 2009, MOL PSYCHIATR, V14, P51, DOI 10.1038/sj.mp.4002099
- Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449
- Yucel K, 2007, PSYCHOPHARMACOLOGY, V195, P357, DOI 10.1007/s00213-007-0906-9
- Zhang X, 2011, J ALZHEIMERS DIS, V24, P739, DOI 10.3233/JAD-2011-101875